Niagen Bioscience, Inc. NAGE

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived Nasdaq

Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries.

On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).

Last close 2.43 2026-10-23
Market cap $192.3M 2026-06-30 share count
52-week range 2.42 - 7.95

Valuation FY2025 figures against the last close

P/S1.5x
P/E12.2x
P/FCF14.2x
EV/EBITDA11.4x
Dividend yield—
Diluted EPS0.20

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $129.4M$99.6M$83.6M$72.0M$67.4M$59.3M$46.3M$31.6M$21.2M$21.7M
Cost of revenue $46.2M$38.0M$32.8M$29.3M$26.0M$24.0M$20.5M$15.5M$10.7M$11.3M
Gross profit $83.2M$61.6M$50.8M$42.8M$41.5M$35.3M$25.8M$16.1M$10.5M$10.4M
R&D $6.3M$6.0M$5.0M$4.8M$3.8M$3.4M$4.4M$5.5M$4.0M$2.5M
SG&A $27.1M$18.4M$25.0M$28.3M$36.4M$30.8M$34.3M$27.1M$17.6M$9.2M
Total operating expenses $66.9M$53.9M$56.4M$61.4M$68.6M$55.1M$57.1M$49.2M$26.9M$13.3M
Operating income $16.3M$7.7M-$5.6M-$18.6M-$27.1M-$19.9M-$31.3M-$33.2M-$16.4M-$2.9M
Interest expense ——$661.0K$3.0K$55.0K$71.0K$847.0K$79.0K$153.0K$333.3K
Pre-tax income $18.2M$8.9M-$4.9M—————-$16.5M-$3.6M
Income tax $810.0K$305.0K$0—————$0$0
Net income $17.4M$8.6M-$4.9M-$16.5M-$27.1M-$19.9M-$32.1M-$33.3M-$11.4M-$2.9M
EPS, basic 0.220.11-0.07-0.24-0.40-0.33————
EPS, diluted 0.200.11-0.07-0.24-0.40-0.33-0.56-0.61-0.26-0.08
Shares, diluted (wtd. avg.) 85.4M78.1M75.0M69.7M67.2M61.1M———37.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $64.8M$44.7M$27.3M$20.4M$28.2M$16.7M$18.8M$22.6M——
Receivables $9.7M$7.8M—$8.5M$5.2M$2.7M$2.2M$4.4M$5.3M$5.9M
Inventory —$9.2M$14.5M$14.7M$13.6M$11.7M$11.5M$8.2M$5.8M$7.9M
Total current assets $96.8M$64.1M$49.5M$46.6M$48.9M$32.2M$33.5M$36.5M$57.2M$15.7M
Property, plant and equipment —————$3.2M$3.8M$3.6M$2.9M$1.8M
Other intangibles $5.7M$359.0K$510.0K$671.0K$857.0K$1.1M$1.3M$1.5M$1.7M$486.2K
Total assets $106.4M$68.3M$55.0M$54.1M$57.8M$38.4M$40.2M$42.2M$62.7M$19.8M
Accounts payable $10.8M$8.5M$10.2M$9.7M$10.4M$9.4M$9.6M$9.5M$3.7M$6.0M
Short-term debt —————————$0
Total current liabilities $19.9M$17.9M$20.6M$17.9M$17.6M$16.5M$15.1M$14.4M$8.1M$8.9M
Long-term debt —————————$0
Total liabilities $29.9M$22.2M$26.5M$25.4M$26.1M$21.9M$19.8M$15.1M$8.9M$9.8M
Retained earnings -$164.5M-$181.9M-$190.5M-$185.5M-$169.0M-$141.8M-$121.9M-$89.8M-$56.6M-$45.2M
Total equity $76.5M$46.1M$28.5M$28.7M$31.7M$16.4M$20.4M$27.2M$53.8M$10.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $13.5M$12.1M$7.1M-$15.1M-$24.2M-$10.6M-$20.4M-$20.9M-$9.8M-$2.9M
Depreciation and amortisation $612.0K$663.0K$870.0K$869.0K$890.0K$871.0K$762.0K$607.0K$510.0K$332.0K
Stock-based compensation $6.1M$3.7M$4.8M$5.7M$6.2M$6.9M$7.2M$6.4M$4.6M$1.2M
Capital expenditure ——————$743.0K$1.3M$1.2M$1.5M
Investing cash flow -$292.0K-$143.0K-$143.0K-$334.0K-$409.0K-$165.0K-$249.0K-$1.8M$4.6M-$1.7M
Financing cash flow $6.9M$5.4M-$90.0K$7.7M$36.1M$8.7M$16.9M-$90.0K$48.9M$754.3K
Buybacks $251.0K$0—————$404.0K$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001386570-26-000022.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Revenue, FY2016: 21.7M Gross profit, FY2016: 10.4M Net income, FY2016: -2.9M Revenue, FY2017: 21.2M Gross profit, FY2017: 10.5M Net income, FY2017: -11.4M Revenue, FY2018: 31.6M Gross profit, FY2018: 16.1M Net income, FY2018: -33.3M Revenue, FY2019: 46.3M Gross profit, FY2019: 25.8M Net income, FY2019: -32.1M Revenue, FY2020: 59.3M Gross profit, FY2020: 35.3M Net income, FY2020: -19.9M Revenue, FY2021: 67.4M Gross profit, FY2021: 41.5M Net income, FY2021: -27.1M Revenue, FY2022: 72M Gross profit, FY2022: 42.8M Net income, FY2022: -16.5M Revenue, FY2023: 83.6M Gross profit, FY2023: 50.8M Net income, FY2023: -4.9M Revenue, FY2024: 99.6M Gross profit, FY2024: 61.6M Net income, FY2024: 8.6M Revenue, FY2025: 129.4M Gross profit, FY2025: 83.2M Net income, FY2025: 17.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $21.7M $21.2M $31.6M $46.3M $59.3M $67.4M $72.0M $83.6M $99.6M $129.4M
Gross profit $10.4M $10.5M $16.1M $25.8M $35.3M $41.5M $42.8M $50.8M $61.6M $83.2M
Net income -$2.9M -$11.4M -$33.3M -$32.1M -$19.9M -$27.1M -$16.5M -$4.9M $8.6M $17.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $4.79B — —
TRLV Trulieve Cannabis Corp. $2.01B — -0.4%
CRON Cronos Group Inc. $1.23B — 24.6%
TLRY Tilray Brands, Inc. $382.7M — 11.5%
CGC Canopy Growth Corp $285.9M — —
USNA USANA HEALTH SCIENCES INC $257.9M 24.1x 8.3%
FTLF FITLIFE BRANDS, INC. $78.4M 13.3x 26.4%
BTMD biote Corp. $30.6M 1.4x -2.5%